Portal de Periódicos da CAPES

Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance

2017; Elsevier BV; Volume: 17; Issue: 10 Linguagem: Inglês

10.1016/s1473-3099(17)30238-4

1474-4457

Julian W. Tang, Tommy Tsan‐Yuk Lam, Hassan Zaraket, W. Ian Lipkin, Steven J. Drews, Todd F. Hatchette, Jean‐Michel Héraud, Marion Koopmans, Asha Mary Abraham, Amal Baraket, Seweryn Bialasiewicz, Miguela A. Caniza, Paul K.S. Chan, Cheryl Cohen, André Corriveau, Benjamin J. Cowling, Steven J. Drews, Marcela Echavarría, Ron A. M. Fouchier, Pieter L.A. Fraaij, Todd F Hachette, Jean‐Michel Héraud, Hamid Jalal, Lance Jennings, Alice Kabanda, Hervé Kadjo, Rafiq Khanani, Evelyn SC Koay, Marion Koopmans, Mel Krajden, Tommy Tsan‐Yuk Lam, Hong Kai Lee, W. Ian Lipkin, Julius J. Lutwama, David Marchant, Hidekazu Nishimura, Pagbajabyn Nymadawa, Benjamin A. Pinsky, Sanjiv Rughooputh, Joseph Rukelibuga, Taslimarif Saiyed, Anita Shet, Theo P. Sloots, JJ Muyembe Tamfum, Julian W. Tang, Stefano Tempia, Sarah Tozer, Florette K. Treurnicht, Matti Waris, Aripuanã Sakurada Aranha Watanabe, Emile Okitolonda Wemakoy,

Viral gastroenteritis research and epidemiology

Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and human metapneumovirus, represent a considerable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative. By contrast with influenza viruses, little is known about the contemporaneous global diversity of these viruses, and the relevance of such for development of pharmaceutical interventions. Although far less advanced than for influenza, antiviral drugs and vaccines are in different stages of development for several of these viruses, but no interventions have been licensed. This scarcity of global genetic data represents a substantial knowledge gap and impediment to the eventual licensing of new antiviral drugs and vaccines for NIRVs. Enhanced genetic surveillance will assist and boost research and development into new antiviral drugs and vaccines for these viruses. Additionally, understanding the global diversity of respiratory viruses is also part of emerging disease preparedness, because non-human coronaviruses and paramyxoviruses have been listed as priority concerns in a recent WHO research and development blueprint initiative for emerging infectious diseases. In this Personal View, we explain further the rationale for expanding the genetic database of NIRVs and emphasise the need for greater investment in this area of research.